Physician profile
Adam D Devore
NPI 1558560987
$111,825.10
in general payments reported to CMS, 2019-2025
12 companies · $9,378 in 2025
The $9,378 reported for 2025 was more than what 98% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21K · 2020: $29K · 2021: $24K · 2022: $13K · 2023: $4,292 · 2024: $11K · 2025: $9,378.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $13K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,750 · Food and Beverage: $1,043 · Travel and Lodging: $947.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $12,852.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,750.00 |
| Food and Beverage | $1,042.81 |
| Travel and Lodging | $947.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $50,010.12 | 2019-2025 | Lifevest |
| Astrazeneca Pharmaceuticals Lp | $13,403.37 | 2019-2022 | |
| Abiomed | $12,031.55 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $9,362.39 | 2019 | |
| Livanova USA, INC. | $9,175.00 | 2019-2022 | |
| Novo Nordisk INC | $8,907.50 | 2022-2025 | |
| Amgen INC. | $3,156.25 | 2019-2020 | |
| Astrazeneca Uk Limited | $2,277.04 | 2019 | |
| Abbott Laboratories | $2,239.96 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $1,245.00 | 2025 | |
| Boston Scientific Corporation | $16.92 | 2025 | Accolade Sr |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Devore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.